by David Cassak
There's a natural and understandable temptation to equate greater complexity in medical devices with greater value, both clinical and commercial....
Cameron Health: Is This The Cure For An Ailing ICD Market?
Listen to this article
Ten years ago, the ICD market was booming, now it's not, despite studies that show the device is underutilized. The increasing complexity of CRM devices, and in particular ICDs, has brought a host of problems - including major product recalls that in turn have created caution on the part of patients - and has done little to grow the market beyond single digits in recent years. Cameron Health believes it has the answer for a truly disruptive ICD with a contrarian twist: a simpler device that addresses major problems such as lead failures, inappropriate shocks, and the burdens of complexity.
Candid conversations with C-suite leaders.
More from In Vivo Archive
In Partnership with Cerba Research
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Digital clinical trials, a trend sparked by the COVID-19 pandemic that has held the biopharma industry’s interest, are changing the way patients interact with research and improving access, says Medable’s CEO.
• By
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
• By
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
More from In Vivo
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.